Winn-Dixie to offer free cholesterol screenings, guides this month
JACKSONVILLE, Fla. — Winn-Dixie is putting an emphasis on heart health by highlighting its pharmacy offerings.
The company said guests can receive free cholesterol screenings at Winn-Dixie pharmacies and is partnering with the Agency for Healthcare Research and Quality to offer a free treating high cholesterol guide, which is available in English and Spanish, in honor of American Heart Month.
“As part of the healthcare team, your Winn-Dixie pharmacist plays a significant role in the management and prevention of cardiovascular disease,” Winn-Dixie VP pharmacy John Fegan said. “With pharmacies in a majority of our stores, Winn-Dixie is distinctively positioned to offer guests expert consultation, disease prevention information and medications alongside an abundant selection of heart healthy meal and dietary solutions.”
To learn more about additional pharmacy services offered at Winn-Dixie can be found here.
Amber Pharmacy adopts Armada’s prior authorization system
FLORHAM PARK, N.J. — Specialty pharmacy company Amber Pharmacy has implemented a prior authorization system provided by Armada Health Care, Amber said.
Amber announced that it had incorporated Armada’s Web-based ApproveRx system into its daily pharmacy operations, saying that it would help simplify the prior authorization process for prescribers and pharmacies. Prior authorizations have traditionally required extra staffing time and resources to locate the correct form from thousands of different insurance forms varying by drug, payer and plan.
"Prescribers and pharmacies of all sizes are utilizing our ApproveRx.com site to improve their operational efficiencies and address the challenges of the prior authorization process," Armada CEO Lawrence Irene said. "ApproveRx instantaneously produces the correct insurance form for the drug entered by payer and plan. The process can be completed online and submitted by the user with a stroke of a key or printed for traditional faxing to the insurance carrier."
BI study: No drug interaction between Aggrenox, omeprazole
RIDGEFIELD, Conn. — An antiplatelet medication created by Boehringer Ingelheim is not affected when co-administered with a proton-pump inhibitor, according to results of a drug interaction study.
The drug maker — which presented the multiple-dose, open-label, randomized crossover study (that included 60 healthy subjects) at the International Stroke Conference in New Orleans — examined the interaction between Aggrenox (aspirin/extended-release dipyridamole) capsules in the 25-mg/200-mg strength and omeprazole. The drug maker said that it wanted to show that while omeprazole is shown to interact with some medications, it did not interact with Aggrenox.
“Omeprazole has been shown to interact with some medications that are metabolized through the CYP2C19 system. Aggrenox is not metabolized through the CYP2C19 system, however we wanted to understand if it would be affected when given together with omeprazole,” said John Smith, SVP clinical development and medical affairs at Boehringer Ingelheim. “We are pleased that these data have shown that omperazole does not interact with Aggrenox.”